Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Jan 22, 2021

Chugai and Taisho Terminate the Co-Marketing Agreement of Edirol®, a Treatment for Osteoporosis

Chugai Pharmaceutical Co., Ltd.
Taisho Pharmaceutical Co., Ltd.

TOKYO, January 22, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Taisho Pharmaceutical Co., Ltd. announced termination of the agreement between both companies regarding co-marketing of Edirol® Capsules 0.5 µg and 0.75 µg (hereafter, “Edirol”), a treatment for osteoporosis for which Chugai has a marketing authorization.

In May 2008, both companies entered into an agreement for co-development and marketing of Edirol. They have co-marketed Edirol and engaged in providing information in Japan since the launch of the product in April 2011. However, they have decided to terminate the agreement regarding co-marketing, following discussions on future marketing policies.

As such, Taisho will stop marketing and providing information on Edirol on April 10, 2021, while Chugai will solely be responsible for these activities from April 11, 2021.

Chugai and Taisho will corporate to accomplish a smooth transition. During the transition period, both companies will maintain the same level of product supply and adequate commercial activities to satisfy any medical needs.

Edirol® is a trademark of Chugai.

Contact Information:

Corporate Communications Dept.,
Chugai Pharmaceutical Co., Ltd.

Contact from the press
Media Relations Group
TEL: +81-3-3273-0881
Mail: pr@chugai-pharm.co.jp

Contact from analysts/investors
Investor Relations Group
TEL: +81-3-3273-0554
Mail: ir@chugai-pharm.co.jp

Corporate Communications Dept.,
Taisho Pharmaceutical Co., Ltd.

Contact from the press
Media PR Group
TEL: +81-3-3985-1115
Mail: pr@taisho.co.jp

Contact from analysts/investors
IR Group
TEL: +81-3-3985-1115
Mail: ir@taisho.co.jp

  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top